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Abstracts / Urological Science 26 (2015) S1eS25 S5Conclusion: This case emphasizes the potential for stone formation when
non-absorbable sutures are used in the urinary tract. Whenwe encounter a
urolithiasis that locates over the place where a prior surgical procedure
was done, we should keep in mind to ﬁnd out any possible non-absorbable
material remains.
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Purpose: We previously demonstrated that renal sensory function in
response to mechano- and chemo-stimulationwas impaired in rat kidneys
with hyperoxaluria and/or calcium oxalate (CaOx) crystals. The transient
receptor potential vanilloid 1 channel (TRPV1) is known to present in rat
kidneys and responsible for activation of afferent renal nerve activity
(ARNA) and induction of diuretic renorenal reﬂex. The present study
therefore tests whether TRPV1 dysfunction may be the underlying
mechanism for contribution to sensory impairment seen in the hyper-
oxaluric kidney.
Materials and Methods: Acute hyperoxaluria was induced by intrapelvic
perfusion of oxalate into renal pelvis, a tissue area mostly originated for
renal sensory nerves. Chronic hyperoxaluria was induced in rats after fed
with fed with 5% hydroxyl-L-proline (HP) in daily diet for 42 days. Renal
nerves in the left kidney were carefully isolated for recording of ARNA and
efferent renal sympathetic nerve activity (ERSNA). Changes in the cortical
microvascular blood ﬂow (CMBF) weremonitored by ultrasonic ﬂowmeter.
Renorenal reﬂex response was tested by rising intrapelvic pressure (IPP) or
intrapelvic perfusion of high salt solution in the left kidney, and urine
output and sodium excretion in the contralateral (right) kidney were
collected. Renal pelvic efﬂuent was collected for determination of the
amount of sensory neuropeptide substance P (SP) release. Changes in
TRPV1 and neurokinin-1 receptor (NK-1R) expression in renal pelvis were
examined by Western blot analysis.
Results: Compared to vehicle-treated kidney, acute perfusion of oxalate
into renal pelvis resulted in persistently decreased ARNA, increased
ERSNA, decreased CMBF, and impaired renorenal reﬂex after 4 h of treat-
ment. SP release was increased after oxalate treatment, this associated
with NK-1R downregulation. These however were attenuated by co-
treatment of speciﬁc TRPV1 blocker SB-366791. As a polymodal sensor, our
results indicate TRPV1 may act as an oxalate sensor. In HP rats, ARNA in
response to chemo- and mechano-stimulation, and ARNA-mediated reﬂex
control on ERSNA and renal excretion were impaired after 7 days of
treatment and thereafter. Severe reductions were found after 42 days of
hyperoxaluria with CaOx deposition. These associated with increases in
TRPV1 expression and SP release, and NK-1R downregulation in renal
pelvis.
Conclusion: Our results clearly indicate that TRPV1 hyperfunction con-
tributes to renal sensory impairment in the hyperoxaluric rats, which led
to too much SP release, and NK-1R desensitization in nerve endings of
renal pelvis. Deﬁciency in renal sensation blinds the kidney to the presence
of hyperoxaluria as well as the formation of CaOx.
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Purpose: Cell therapy has been demonstrated to be beneﬁcial for treat-
ment of disease by enhancing self and/or endogenous repair in various
organ tissues. Whether cell therapy is effective to alleviate tubular cell
injury caused by hyperoxaluria during kidney stone formation is still un-
clear. This study aims to test whether mobilization of endogenous stemcells from bone marrow may protect kidneys against hyperoxaluria and
further calcium oxalate (CaOx) crystal deposition.
Materials and Methods: Male Wistar rats were divided into control rats
received standard diet and hyperoxaluric rats fed with 5% hydroxyl-L-
proline (HP) in daily diet for 7 and 28 days. Another group of HP rats was
received plerixafor, a selective CXCR4 blocker (AMD3100), continuously
via a subcutaneous implant of mini-osmotic pump as CXCR4 antagonism is
known to mobilize endogenous stem/progenitor cells into circulation. The
24 h of urine samplewas collected to evaluate degree of supersaturation by
estimation of the ionic activity of calcium oxalate (CaOx) and the amount
of calcium crystal excretion in urine sedimentation. Blood sample was
collected to evaluate the circulating level of CD34+CXCR4+ cells. Crystal
distribution within the kidneys will be examined by counting crystal de-
posits by von Kossa staining. Protein expressions in renal tissues and in
urine were quantitatively analyzed.
Results: Compared to the vehicle-treated HP rats, plerixafor signiﬁcantly
attenuated CaOx crystal deposition and increased the amount of urinary
sediment after 28-day treatment but without any effect on hyperoxaluria
and supersaturation at both time-points. Interestingly, circulating
CD34+CXCR4+ cells were markedly elevated in the plerixafor-treated rats
after 7 days and persisted thereafter. This was associated with an increase
in renal expression of stromal cell-derived factor 1 (SDF-1) in the plerix-
afor-treated kidneys for 7 and 28 days. The urinary contents of two anti-
crystallization molecules, osteopontin (OPN) and Tamm-Horsfall protein
(THP), in the plerixafor-treated HP rats were signiﬁcantly increased as
compared to those in the vehicle-treated HP groups for 7 and 28 days. This
associated with an attenuation of enzymuria for tubular damage markers,
a- and m-glutathione-S-transferase (GST). Moreover, renal contents of OPN,
THP, aGST, and mGST in the plerixafor-treated HP rats were higher than
those in the vehicle-treated HP groups at both time-points.
Conclusion: These results clearly indicate that the anticrystallization ef-
fect of plerixafor is possibly related to an increase in CD34+CXCR4+ cell
homing to the injured hyperoxaluric kidney with a higher SDF-1 expres-
sion, which attenuates tubular cell injury and against CaOx crystal for-
mation by maintenance of renal production of OPN and THP. Attenuation
of cell debris desquamated from damaged tubular cells may prevent
seeding effect for calcium crystal formation in growth.
PD3-4:
LONG-TERM PRESCRIPTION OF a-BLOCKERS DECREASE THE RISK OF
RECURRENT UROLITHIASIS NEEDED FOR SURGICAL INTERVENTION-A
NATIONWIDE POPULATION-BASED STUDY
Chia-Chu Liu 1,2,3, Hui-Min Hsieh 4, Chia-Fang Wu4, Tusty-Jiuan
Hsieh 5, Shu-Pin Huang 1,2, Yii-Her Chou 1,2, Chun-Nung Huang 1,2, Wen-
Jeng Wu1,2, Ming-Tsang Wu4,6. 1Department of Urology, College of
Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan;
2Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung City, Taiwan; 3Depratment of Urology,
Pingtung Hospital, Ministry of Health and Welfare, Executive Yuan,
Pingtung, Taiwan; 4Department of Public Health, Kaohsiung Medical
University, Kaohsiung City, Taiwan; 5Department of Medical Genetics,
College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan;
6Department of Family Medicine, Kaohsiung Medical University Hospital,
Kaohsiung Medical University, Kaohsiung City, Taiwan
Purpose: a1 receptors and subtypes have been conﬁrmed to distribute in
human pelvis and calyces recently. As used in ureteral stones, a-blocker
treatment may facilitate kidney stone passage and long-term prescription
of a-blocker may decrease the risk of recurrent urolithiasis. The aim of this
study is to determine if use of a-blockers 180 days or more can decrease
the risk of recurrent urolithiasis needed for surgical intervention.
Materials and Methods: A representative database of 1,000,000 patients
from Taiwan's National Health Insurance was analyzed. Eligible patients
were those who had received the ﬁrst-time procedure for upper urinary
stone removal, including extracorporeal shock-wave lithotripsy, ureter-
orenoscopic lithotripsy, or both, between 2000 and 2010. After completing
a 180-day treatment for ﬁrst event, patients were prospectively followed-
up until a second set of stone procedures was performed (proxy of stone
recurrence), loss to follow-up, or end of study. The effect of percentage of
total number of days of a-blocker use on need for second set of stone
